Mizuho raises GE HealthCare stock price target to $90 on growth

Mizuho raised its price target for GE HealthCare (GEHC) to $90 from $85, citing 6% organic growth and stable demand for imaging capital. The stock trades at $75.82. GEHC reported Q3 2026 revenue of $5.5B, 6.2% organic growth, and raised its full-year outlook. Stifel and BofA also updated their price targets.

Original reporting
Published Oct 29, 2026, 10:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 10:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$GEHC
Bullish
high confidence
Mentioned
$GEHC
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$GEHCBullishMed
01

Why it matters

The combination of higher earnings and upgraded targets creates a bullish catalyst for GEHC.

02

Market read

GEHC's earnings beat and multiple target upgrades provide a clear short‑term upside catalyst.

03

What to watch

Potential headwinds from Middle East conflict and Medicaid cuts could temper growth.

Relevance 8/10Novelty 8/10Timing: today

Background

The article combines analyst price‑target upgrades with the company's Q3 earnings release.

Company-level read

Ticker impact

$GEHCBullishHigh confidence
Context

Mizuho raised its price target on GE HealthCare to $90 and reported Q3 2026 earnings with $5.5B revenue and 25.1% EPS growth.

Expected impact

likely upward pressure as the market prices in higher earnings and target raises

Evidence & confidence

Target hikes from multiple analysts and better‑than‑expected results provide a clear catalyst for price appreciation.

Market effects

Strong results may lift other medical‑technology and imaging equipment stocks.

U.S. healthcare sector could see modest gains.

Reinforces confidence in global hospital‑capital spending trends.

Counterpoint

If the PCS segment underperforms, the price targets may be overly optimistic.

Key entities

  • Mizuho

    Raised GEHC price target to $90.

  • Stifel

    Raised price target to $90.

  • BofA Securities

    Raised price target to $84.

Related articles

$GEHCMed

GE HealthCare Wins FDA Nod for AI Feeding Tube Detection Software

GE HealthCare received FDA clearance for Critical Care Suite 3.0, an AI software for feeding tube detection in X-ray imaging. The software supports both adult and pediatric patients, enhancing the company's AI-enabled imaging portfolio. GEHC shares rose 2% post-announcement, with a market cap of $37.51B. The software demonstrated high accuracy in testing, potentially increasing demand for GEHC's mobile imaging systems.

$GEHCMed

GE HealthCare Lands FDA Clearance for On-Device Feeding Tube AI

GE HealthCare received FDA clearance for Critical Care Suite 3.0, an AI software for mobile X-ray devices that detects feeding tubes in adults and children. The algorithm, running on-device, achieved 99.2% sensitivity and 91.6% localization accuracy. The company aims to enhance ICU and emergency department workflows, with plans for further AI releases in 2027.

$GEHCMedAI 9/10

GE HealthCare Technologies Inc.: GE HealthCare's Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial

GE HealthCare (GEHC) announced positive Phase 2 results for its MRI contrast agent mangaciclanol, meeting the primary endpoint and showing similar diagnostic preference to gadobutrol. The trial will advance to Phase 3, with mangaciclanol receiving FDA Fast Track designation. GEHC plans to present preliminary results at RSNA 2026.

$GEHCMed

GE HealthCare’s Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial

GE HealthCare (GEHC) announced positive Phase 2 results for its MRI contrast agent mangaciclanol, advancing it to Phase 3 trials. The agent showed similar diagnostic performance to gadolinium-based agents and was well-tolerated. GEHC aims to address concerns with current contrast agents, such as tissue retention and supply chain issues. The FDA has granted mangaciclanol Fast Track designation.